EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Discovery of dCDK9-202 as a Highly Potent and Selective PROTAC CDK9 Degrader with Strong In Vivo Antitumor Activity

Lin Ma, Long Xie, Yue Wang, Xian Guan, Ying Zhang, Hanjun Guo, Jiawei Zhou, Jiyang Liu, Xingze Huang, Chunyu He, Ye Chen, Liang Xu und 1 weitere

Journal of Medicinal Chemistry · 23.10.2025 · 68 (20) · 21172-21186

DOI: 10.1021/acs.jmedchem.5c01111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 09.10.2025. Verfasst von Lin Ma und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education) of the Second Affiliated Hospital and I…. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 9, Antineoplastic Agents, Protein Kinase Inhibitors, Drug Discovery. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Ministry of Education, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a promising cancer therapeutic target, the development of highly efficient and selective small-molecule drugs targeting CDK9 remains a significant challenge due to the similarity of its ATP-binding site to that of other CDKs. Here, we report our design, synthesis, and evaluation of CDK9 degraders with high selectivity based upon the concept of PROTAC. The representative compound dCDK9-202 demonstrates a DC50 value of 3.5 nM and Dmax > 99% in inducing rapid CDK9 degradation in the TC-71 cell line. Notably, dCDK9-202 achieves significant cell growth inhibition with an IC50 value of 8.5 nM in the TC-71 cell line and also low nanomolar IC50 values in multiple cancer cell lines originating from the lung, liver, bone, and brain. Moreover, intravenous administration of dCDK9-202 effectively inhibits TC-71 tumor growth without any signs of toxicity in mice. This promising CDK9 degrader dCDK9-202 has a high potential for advanced preclinical development in the treatment of CDK9-addicted human cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase 9Antineoplastic AgentsProtein Kinase InhibitorsDrug DiscoveryHumansAnimalsMiceCell Line, TumorCell ProliferationStructure-Activity RelationshipDrug Screening Assays, AntitumorMice, Nude

Substanzen

Cyclin-Dependent Kinase 9Antineoplastic AgentsCDK9 protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education) of the Second Affiliated Hospital and Institute of Translational Medicine, Zhejiang University School of Medi…
  • Institute of Biochemistry, College of Life Sciences, Zhejiang University, Hangzhou 310058, China.
  • Department of Surgical Oncology, Children's Hospital Zhejiang University School of Medicine, Hangzhou 310052, China.
  • Pediatric Cancer Research Center, National Clinical Research Center for Child Health, Hangzhou 310052, China.
  • Cancer Center of Zhejiang University, Hangzhou 310029, China.
  • Department of Radiation Oncology (Key Laboratory of Cancer Prevention and Intervention China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Zhejiang Province, China), The Second…

Förderung

  • State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Ministry of Education
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China
  • Natural Science Foundation of Zhejiang Province

Zitieren

APA

Ma, L., Xie, L., Wang, Y., Guan, X., Zhang, Y., Guo, H., Zhou, J., Liu, J., Huang, X., He, C., Chen, Y., Xu, L., & Han, X. (2025). Discovery of dCDK9-202 as a Highly Potent and Selective PROTAC CDK9 Degrader with Strong In Vivo Antitumor Activity. Journal of Medicinal Chemistry, 68(20), 21172-21186. https://doi.org/10.1021/acs.jmedchem.5c01111

Vancouver

Ma L, Xie L, Wang Y, Guan X, Zhang Y, Guo H, et al. Discovery of dCDK9-202 as a Highly Potent and Selective PROTAC CDK9 Degrader with Strong In Vivo Antitumor Activity. Journal of Medicinal Chemistry. 2025;68(20):21172-21186. doi:10.1021/acs.jmedchem.5c01111

BibTeX
@article{Ma2025,
  author = {Ma, Lin and Xie, Long and Wang, Yue and Guan, Xian and Zhang, Ying and Guo, Hanjun and Zhou, Jiawei and Liu, Jiyang and Huang, Xingze and He, Chunyu and Chen, Ye and Xu, Liang and Han, Xin},
  title = {Discovery of dCDK9-202 as a Highly Potent and Selective PROTAC CDK9 Degrader with Strong In Vivo Antitumor Activity},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {20},
  pages = {21172--21186},
  doi = {10.1021/acs.jmedchem.5c01111}
}
Kostenlos starten →